Abstract: Pyrimidine derivatives of the formula (I) and physiologically acceptable salts thereof, in which R1, R2, R3, R4, W, X, Y and Z are as defined in claim 1, exhibit phosphodiesterase V inhibition and can be employed for the treatment of diseases of the cardiovascular system and for the treatment and/or therapy of potency disorders

Abstract: The present invention relates to malonamide derivatives of formula A-D-B-1, as inhibitors of raf-kinase and the use of the compounds of formula (I) for the manufacture of a pharmaceutical composition.

Abstract: The present invention relates to a novel process for the preparation of N-substituted cyclic imides. N-substituted cyclic imides are valuable intermediates which can be employed, for example, for the synthesis of pharmacologically valuable compounds.

Abstract: Pyrimidine derivatives of formula (I) and 1

Abstract: The present invention relates to an NHE-1 selective Na+/H+ antiporter inhibitor N-(4,5-bismethanesulfonyl-2-methylbenzoyl)guanidine, hydrochloride, to its hydrochloride hydrate, and to a process for the preparation.

Abstract: Chroman derivatives of the formula I ##STR1## wherein R.sup.1 to R.sup.8 have the meanings defined herein, and their salts have an effect on the cardiovascular system.

Abstract: Chroman derivatives of the formula I ##STR1## wherein R.sup.1 to R.sup.8 have the meanings defined herein, and their salts have an effect on the cardiovascular system.

Abstract: Cyclic sulphones of formula (I) are disclosed, in which: R.sup.1 and R.sup.2 each independently of one another stand for H, A, CF.sub.3, CH.sub.2 F, CHF.sub.2, C.sub.2 F.sub.5, Hal, OH, OA, NH.sub.2, NHA, NA.sub.2, NO.sub.2 or CN; X stands for CR.sup.4 R.sup.5, C.dbd.Z, O, S, NH, NA or NR.sup.3 ; Y stands for CR.sup.6 R.sup.7, C.dbd.Z, O, NH, NA, or NR.sup.3 ; Z stands for O, S, NH, NA, NOH, NOA, CH.sub.2, CHA or CA.sub.2 ; R.sup.4, R.sup.5, R.sup.6 and R.sup.7 each independently of one another stand for H, A, R.sup.3, Hal, OH, OA, SH, SA, NH.sub.2, NHA or NA.sub.2, or alternatively, R.sup.5 and R.sup.6 or R.sup.7 and R.sup.8 can together represent a bond, only one such bond being present in each molecule; R.sup.4 and R.sup.5 together can also stand for O--(CH.sub.2).sub.2 --O or O--(CH.sub.2).sub.3 --O; R.sup.8 and R.sup.9 each independently of one another stand for H or A; A stands for alkyl with 1-6 C atoms; Hal stands for F, Cl, Br or I; and R.sup.

Abstract: Heterocyclyloxybenzoylguanidines of the formula I ##STR1## in which R.sup.1, R.sup.2 and Het have the given meanings, and also the pharmaceutically acceptable salts thereof, exhibit antiarrhythmic properties and act as inhibitors of the cellular Na.sup.+ /H.sup.+ antiporter.

Abstract: Ortho-substituted benzoic acid derivatives of the formula I ##STR1## in which R.sup.1, R.sup.2 and R.sup.3 have the given meanings, and Q is guanidyl, and also their physiologically harmless salts, exhibit antiarrhythmic properties and act as inhibitors of the cellular Na.sup.+ /H.sup.+ antiporter. In addition, the compounds of the formula I, in which R.sup.1 to R.sup.3 and also Q have the given meanings, are suitable for use as valuable intermediates for the preparation of medicaments, in particular of inhibitors of the cellular Na.sup.+ /H.sup.+ antiporter.

Abstract: Alkylbenzoylguanidines of the formula I ##STR1## in which A, R.sup.1, R.sup.2 and R.sup.3 have the given meanings, and their physiologically harmless salts exhibit antiarrhythmic properties and act as inhibitor of the cellular Na.sup.+ /H.sup.+ antiporter.

Abstract: Arylbenzoylguanidines of the formula I ##STR1## in which R.sup.1 R.sup.2, R.sup.3 and Ph have the given meanings herein, and also the physiologically harmless salts thereof, exhibit antiarrhythmic properties and act as inhibitors of the cellular Na.sup.+ /H.sup.+ antiporter.

Abstract: Heterocyclyl-benzoylguanidines of the formula I ##STR1## in which R.sup.1, R.sup.2, R.sup.3 and Het have the meanings given herein, and physiologically unobjectionable salts thereof, display antiarrhythmic properties and act as inhibitors of the cellular Na.sup.+ /H.sup.+ antiporter.

Abstract: Fluorine-containing benzoylguanidines of the formula I ##STR1## in which R.sup.1, R.sup.2 and R.sup.3 have the meanings indicated, and their physiologically acceptable salts, have antiarrhythmic properties and act as inhibitors of the cellular Na.sup.+ /H.sup.+ antiporter, for example.

Abstract: 4-Sulfonyl- or 4-sulfinylbenzoylguanidines of the formula I ##STR1## in which R.sup.1, R.sup.2, R.sup.3, R.sup.6 and n have the meanings indicated, and their physiologically acceptable salts exhibit antiarrhythmic properties and, act as inhibitors of the cellular Na.sup.+ /H.sup.+ antiporter.

Abstract: Alkyl-benzoylguanidines of the formula I ##STR1## wherein R.sup.1, R.sup.2 and R.sup.3 have the meanings given, and physiologically acceptable salts thereof show antiarrhythmic properties and act as inhibitors of the cellular Na.sup.+ /H.sup.+ antiporter.

Abstract: Benzoylguanidines of the formula I ##STR1## wherein R.sup.1 and R.sup.2 have the meanings indicated herein, and their physiologically acceptable salts, show anti-arrhythmic properties and act as inhibitors of the cellular NA.sup.+ /H.sup.+ antiporter.

Abstract: 4-Mercaptobenzoylguanidines of the formula I ##STR1## in which A, R.sub.1, R.sub.2 and R.sub.3 have the meanings given, and the physiologically unobjectionable salts thereof exhibit antiarrhythmic properties and are active as inhibitors of the cellular Na.sup.+ /H.sup.+ antiporter.

Abstract: Diterpenes of the formula I ##STR1## in which R.sup.1 is --CH.sub.2 --C(CH.sub.3).dbd.CH--R.sup.3 or --CH.sub.2 --CH(CH.sub.3)--CH.sub.2 --R.sup.3,R.sup.3 is --CH.sub.2 OH, --CHO, --COOH or --COOR.sup.4,R.sup.4 is alkyl having 1 to 5 C atoms,A is ##STR2## and R.sup.2 is H, pentoses, hexoses, di-/oligosaccharides or amino sugars,are suitable for production of medicaments having immunomodulatory action, in particular stimulating T-cells.

Abstract: Piperidine and piperazine derivatives of formula I ##STR1## wherein R.sup.1 and R.sup.2 are H or A,R.sup.3, R.sup.4 and R.sup.5 are each independently H, Hal, OH, OA, OAc, NO.sub.2, NH.sub.2, NHAc, NHSO.sub.2 A or CN, orR.sup.3 and R.sup.4 together are --O--(CH.sub.2).sub.m --O--,n is 0, 1 or 2X is O or CH.sub.2, if n=0 or 2, or CH.sub.2, NH, NA or NAc, if n=1,Y is CH or N,m is 1 or 2,Hal is F, Cl, Br or I,A is C.sub.1-6 -alkyl,Ac is C.sub.1-8 -alkanoyl C.sub.1-10 -aralkanoyl or C.sub.7-11 -aroyl,and their physiologically acceptable salts show antiarrhythmic effects.